source
- FDA grants Capricor three-month extension to review DMD cell therapy dataThe U.S. Food and Drug Administration has given Capricor Therapeutics an additional three months to evaluate its Duchenne muscular dystrophy cell therapy after the agency asked for more information…
- Inhalable modified tRNA restores lung protein function in cystic fibrosis mice, shows promise for genetic diseasesUniversity of Toronto scientists have shown that an inhalable form of modified transfer RNA can safely reach the lungs of mice carrying a nonsense mutation that causes cystic fibrosis. The treatmen…